EP2646553A4 - Compositions and methods for treating androgen receptor dependent disorders including cancers - Google Patents

Compositions and methods for treating androgen receptor dependent disorders including cancers

Info

Publication number
EP2646553A4
EP2646553A4 EP11839515.1A EP11839515A EP2646553A4 EP 2646553 A4 EP2646553 A4 EP 2646553A4 EP 11839515 A EP11839515 A EP 11839515A EP 2646553 A4 EP2646553 A4 EP 2646553A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
androgen receptor
disorders including
including cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11839515.1A
Other languages
German (de)
French (fr)
Other versions
EP2646553A1 (en
Inventor
Jesper Worm
Yixian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/945,551 external-priority patent/US8450290B2/en
Priority claimed from GBGB1101969.2A external-priority patent/GB201101969D0/en
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Publication of EP2646553A1 publication Critical patent/EP2646553A1/en
Publication of EP2646553A4 publication Critical patent/EP2646553A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11839515.1A 2010-11-12 2011-11-11 Compositions and methods for treating androgen receptor dependent disorders including cancers Withdrawn EP2646553A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/945,551 US8450290B2 (en) 2007-11-26 2010-11-12 Methods for treating androgen receptor dependent disorders including cancers
GBGB1101969.2A GB201101969D0 (en) 2011-02-04 2011-02-04 Methods
PCT/US2011/060352 WO2012065051A1 (en) 2010-11-12 2011-11-11 Compositions and methods for treating androgen receptor dependent disorders including cancers

Publications (2)

Publication Number Publication Date
EP2646553A1 EP2646553A1 (en) 2013-10-09
EP2646553A4 true EP2646553A4 (en) 2015-01-07

Family

ID=46051313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11839515.1A Withdrawn EP2646553A4 (en) 2010-11-12 2011-11-11 Compositions and methods for treating androgen receptor dependent disorders including cancers

Country Status (3)

Country Link
EP (1) EP2646553A4 (en)
AU (1) AU2011326034B2 (en)
WO (1) WO2012065051A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092982A1 (en) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc MODULATION OF THE EXPRESSION OF ANDROGEN RECEIVERS
EP4052709A1 (en) * 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
WO2014130932A2 (en) 2013-02-25 2014-08-28 Novartis Ag Novel androgen receptor mutation
US20220193110A1 (en) * 2020-12-17 2022-06-23 Washington University Nxtar-derived oligonucleotides and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055053A2 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
WO2009068033A2 (en) * 2007-11-26 2009-06-04 Santaris Pharma A/S Lna antagonists targeting the androgen receptor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6733776B1 (en) 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
JP2950520B2 (en) 1993-04-02 1999-09-20 アンティキャンサー インコーポレーテド Methods for delivering beneficial formulations to hair follicles
WO1997011170A1 (en) 1995-09-20 1997-03-27 Worcester Foundation For Biomedical Research Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP2141233B1 (en) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Antisense design
US20050153935A1 (en) 2003-09-12 2005-07-14 Iversen Patrick L. Compound and method for treating androgen-independent prostate cancer
EP2299266A1 (en) 2003-12-19 2011-03-23 The Regents of the University of California Methods and materials for assessing prostate cancer therapies
US20050164970A1 (en) 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
US7718684B2 (en) * 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP2076257A4 (en) 2006-09-15 2014-04-16 Belrose Pharma Inc Polymeric conjugates containing positively-charged moieties
CN101534643A (en) 2006-09-15 2009-09-16 安佐制药股份有限公司 Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
US20100048676A1 (en) * 2008-08-04 2010-02-25 University Of Rochester Non-androgen dependent roles for androgen receptor in liver cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055053A2 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
WO2009068033A2 (en) * 2007-11-26 2009-06-04 Santaris Pharma A/S Lna antagonists targeting the androgen receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012065051A1 *

Also Published As

Publication number Publication date
WO2012065051A1 (en) 2012-05-18
EP2646553A1 (en) 2013-10-09
AU2011326034A1 (en) 2013-05-02
AU2011326034B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
HK1246715A1 (en) Compositions and methods for targeted thermomodulation
HK1185623A1 (en) Methods and compositions for treating hemophilia
HK1174064A1 (en) Methods and compositions for cell-proliferation-related disorders
EP2406389A4 (en) Methods and compositions for cell-proliferation-related disorders
IL226401A0 (en) Methods of treating fgf21-associated disorders
EP2552433A4 (en) Compositions and methods for the treatment of somatosensory disorders
SG10201500048SA (en) Compositions and methods for treating glioblastoma gbm
EP2627770A4 (en) Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
ZA201303423B (en) Compositions and methods for treating myelofibrosis
ZA201202557B (en) Method for treating androgen receptor positive cancers
SG10201500124VA (en) Methods and Compositions for Treating Cancer
HK1170150A1 (en) New compositions for treating cmt and related disorders
EP2590674A4 (en) Compositions and methods for treating influenza
EP2550361A4 (en) Compositions and methods for treating neurological disorders
EP2523553A4 (en) Methods and compositions for treating bleeding disorders
EP2911660A4 (en) Compositions and methods for treating estrogen-related medical disorders
EP2912033A4 (en) Compositions and methods for treating estrogen-related medical disorders
EP2646553A4 (en) Compositions and methods for treating androgen receptor dependent disorders including cancers
EP2547368A4 (en) Methods and compositions for the treatment of cancer
EP2582384A4 (en) Compositions and methods for treating cancer
EP2654899A4 (en) Methods for treating neurological conditions and compositions and materials therefor
EP2537031A4 (en) Compositions and methods for treating cancer
IL225959A0 (en) Methods and compositions for assessing and treating cancer
EP2632494A4 (en) Methods and compositions for assessing and treating cancer
PL2637651T3 (en) Composition for treating phonatory and olfactory apparatus disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141204

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20141128BHEP

Ipc: C12N 15/11 20060101AFI20141128BHEP

Ipc: A61K 31/415 20060101ALI20141128BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE INNOVATION CENTER COPENHAGEN A/S

17Q First examination report despatched

Effective date: 20160913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170529

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171010